Search research articles
Contact Us
Filters
Showing results (31-40 of 273) with videos related to
Page
of 28
Sort By:
Annual Review of Medicine
|
January 14, 2011
Pharmacogenetics of endocrine therapy for breast cancer
Michaela J Higgins, Vered Stearns
Journal of the National Cancer Institute
|
April 8, 2004
Déjà vu for breast cancer two?
Vered Stearns, Nancy E Davidson
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 16, 2002
Cooling off hot flashes
Vered Stearns, Daniel F Hayes
Oncotarget
|
April 2, 2021
Innovating and expanding weight loss strategies for breast cancer survivors
Jennifer Y Sheng, Vered Stearns
Expert Reviews in Molecular Medicine
|
November 21, 2008
Pharmacogenetics and breast cancer endocrine therapy: CYP2D6 as a predictive factor for tamoxifen metabolism and drug response?
Vered Stearns, James M Rae
JAMA Oncology
|
July 17, 2015
Gene Mutation Profiling of Breast Cancers for Clinical Decision Making: Drivers and Passengers in the Cart Before the Horse
Vered Stearns, Ben Ho Park
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 6, 2013
Reply to K.I. Pritchard
N Lynn Henry, Vered Stearns
Breast Cancer Research and Treatment
|
October 14, 2010
One size does not fit all: quality of life during adjuvant aromatase inhibitor therapy
N Lynn Henry, Vered Stearns
Current Oncology Reports
|
April 29, 2010
CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance
Michaela J Higgins, Vered Stearns
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 24, 2013
Treatment-emergent effects may predict benefit from endocrine therapy
N Lynn Henry, Vered Stearns
Page
of 28
Search research articles
Search
Showing results (31-40 of 273) with videos related to
Sort By:
Page
of 28
Annual Review of Medicine
|
January 14, 2011
Pharmacogenetics of endocrine therapy for breast cancer
Michaela J Higgins, Vered Stearns
Journal of the National Cancer Institute
|
April 8, 2004
Déjà vu for breast cancer two?
Vered Stearns, Nancy E Davidson
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 16, 2002
Cooling off hot flashes
Vered Stearns, Daniel F Hayes
Oncotarget
|
April 2, 2021
Innovating and expanding weight loss strategies for breast cancer survivors
Jennifer Y Sheng, Vered Stearns
Expert Reviews in Molecular Medicine
|
November 21, 2008
Pharmacogenetics and breast cancer endocrine therapy: CYP2D6 as a predictive factor for tamoxifen metabolism and drug response?
Vered Stearns, James M Rae
JAMA Oncology
|
July 17, 2015
Gene Mutation Profiling of Breast Cancers for Clinical Decision Making: Drivers and Passengers in the Cart Before the Horse
Vered Stearns, Ben Ho Park
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 6, 2013
Reply to K.I. Pritchard
N Lynn Henry, Vered Stearns
Breast Cancer Research and Treatment
|
October 14, 2010
One size does not fit all: quality of life during adjuvant aromatase inhibitor therapy
N Lynn Henry, Vered Stearns
Current Oncology Reports
|
April 29, 2010
CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance
Michaela J Higgins, Vered Stearns
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 24, 2013
Treatment-emergent effects may predict benefit from endocrine therapy
N Lynn Henry, Vered Stearns
Page
of 28